# **Special Issue**

# Comprehensive Strategies in Cancer Immunotherapy

# Message from the Guest Editor

Cancer immunotherapy has evolved significantly over the past century, beginning with early theories and experimental treatments, and progressing to the modern era, which is marked by groundbreaking innovations like immune checkpoint inhibitors, CAR-T therapies, TIL therapy, and cancer vaccines. These advancements have fundamentally shifted the paradigm of cancer patient management. Today, immunotherapy stands at the forefront of cancer treatment, ushering in a new era that offers renewed hope to patients.

As research delves deeper into the mechanisms governing immune cell function and their interactions with the tumor microenvironment, even more promising therapeutic options are on the horizon. The field of neoadjuvant therapy has gained significant attention, with ongoing clinical trials and innovative approaches focused on improving clinical outcomes across a range of cancer types.

The future of cancer treatment and management lies in the integration of combination therapies and predictive biomarkers to enable more personalized, targeted, and effective treatments, ultimately leading to better outcomes and advancing the overall quality of healthcare.

# **Guest Editor**

Dr. Yee Peng Phoon Cleveland Clinic Foundation, Cleveland, OH, USA

## Deadline for manuscript submissions

30 November 2025



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/237453

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

#### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

